SG11201606018UA - Binding proteins and methods of use thereof - Google Patents

Binding proteins and methods of use thereof

Info

Publication number
SG11201606018UA
SG11201606018UA SG11201606018UA SG11201606018UA SG11201606018UA SG 11201606018U A SG11201606018U A SG 11201606018UA SG 11201606018U A SG11201606018U A SG 11201606018UA SG 11201606018U A SG11201606018U A SG 11201606018UA SG 11201606018U A SG11201606018U A SG 11201606018UA
Authority
SG
Singapore
Prior art keywords
methods
binding proteins
proteins
binding
Prior art date
Application number
SG11201606018UA
Inventor
Kalyani Mondal
Betty Chan Li
Yu Chen
Taruna Arora
Hugo Matern
Wenyan Shen
Original Assignee
Ngm Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ngm Biopharmaceuticals Inc filed Critical Ngm Biopharmaceuticals Inc
Publication of SG11201606018UA publication Critical patent/SG11201606018UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
SG11201606018UA 2014-01-24 2015-01-23 Binding proteins and methods of use thereof SG11201606018UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461931531P 2014-01-24 2014-01-24
PCT/US2015/012731 WO2015112886A2 (en) 2014-01-24 2015-01-23 Binding proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11201606018UA true SG11201606018UA (en) 2016-08-30

Family

ID=53678415

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201806108TA SG10201806108TA (en) 2014-01-24 2015-01-23 Binding proteins and methods of use thereof
SG11201606018UA SG11201606018UA (en) 2014-01-24 2015-01-23 Binding proteins and methods of use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201806108TA SG10201806108TA (en) 2014-01-24 2015-01-23 Binding proteins and methods of use thereof

Country Status (30)

Country Link
US (5) US9738716B2 (en)
EP (2) EP3738981A1 (en)
JP (3) JP6837840B2 (en)
KR (1) KR102489475B1 (en)
CN (1) CN106662577B (en)
AU (1) AU2015209131B2 (en)
BR (1) BR112016017248A8 (en)
CA (1) CA2937898A1 (en)
CL (1) CL2016001868A1 (en)
CY (1) CY1123163T1 (en)
DK (1) DK3097122T3 (en)
ES (1) ES2808340T3 (en)
HR (1) HRP20200881T1 (en)
HU (1) HUE050279T2 (en)
IL (1) IL246921B (en)
LT (1) LT3097122T (en)
MX (1) MX2016009555A (en)
MY (1) MY191944A (en)
NZ (1) NZ722377A (en)
PE (1) PE20170256A1 (en)
PH (1) PH12016501644A1 (en)
PL (1) PL3097122T3 (en)
PT (1) PT3097122T (en)
RS (1) RS60593B1 (en)
RU (1) RU2701434C2 (en)
SG (2) SG10201806108TA (en)
SI (1) SI3097122T1 (en)
UA (1) UA119863C2 (en)
WO (1) WO2015112886A2 (en)
ZA (1) ZA201605151B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012279237B2 (en) 2011-07-01 2016-09-29 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
ES2828505T3 (en) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Compositions and methods for the treatment of metabolic disorders and diseases
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
RU2675514C2 (en) 2012-12-27 2018-12-19 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2014111744A1 (en) 2013-01-16 2014-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
EP3062881B1 (en) 2013-10-28 2019-10-02 NGM Biopharmaceuticals, Inc. Cancer models and associated methods
TWI728373B (en) 2013-12-23 2021-05-21 美商建南德克公司 Antibodies and methods of use
DK3097122T3 (en) 2014-01-24 2020-08-10 Ngm Biopharmaceuticals Inc ANTIBODIES BINDING BETA-KLOTHO DOMAIN 2 AND METHODS OF USING IT
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
JP6308699B2 (en) 2014-09-08 2018-04-11 国立大学法人大阪大学 Preventive or therapeutic agent for demyelinating disease
CA2964782A1 (en) 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) * 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CN108350072B (en) 2015-08-03 2022-05-24 诺华股份有限公司 Methods of treating FGF 21-associated disorders
KR20180037275A (en) 2015-08-24 2018-04-11 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Biopharmaceutical composition
AR106133A1 (en) 2015-09-24 2017-12-13 Genentech Inc METHODS FOR THE TREATMENT OF EPILEPSY
EP3377090B1 (en) 2015-11-09 2021-04-07 NGM Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
CN107614529B (en) * 2015-11-17 2019-11-12 苏州盛迪亚生物医药有限公司 PD-L1 antibody, its antigen-binding fragment and its medical usage
MX2018016257A (en) 2016-07-07 2019-11-21 Therachon Sas Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof.
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
US20240076332A1 (en) * 2016-10-04 2024-03-07 Svar Life Science Ab FGF21 Responsive Reporter Gene Cell Line
AU2018218557B9 (en) * 2017-02-08 2021-06-24 Novartis Ag FGF21 mimetic antibodies and uses thereof
CN111836634A (en) * 2017-09-20 2020-10-27 辉瑞大药厂 Treatment of abnormal visceral fat deposition using soluble fibroblast growth factor receptor 3(SFGFR3) polypeptides
EP3849605A4 (en) 2018-09-10 2022-06-15 Cold Spring Harbor Laboratory Methods for treating pancreatitis
WO2020218823A1 (en) * 2019-04-22 2020-10-29 연세대학교 산학협력단 Composition containing, as active ingredient, klotho proteins or genes encoding same
CN110616195B (en) * 2019-10-11 2021-05-04 江南大学 Metformin monoclonal antibody hybridoma cell strain and application thereof
US11891615B2 (en) 2020-06-10 2024-02-06 Gail Marion Humble Process to produce Klotho protein in vitro
US20220010021A1 (en) * 2020-07-02 2022-01-13 Sanofi FGFR1/KLB Targeting Agonistic Antigen-Binding Proteins and Conjugates Thereof with GLP-1R Agonistic Peptides
CN113444730A (en) * 2021-03-17 2021-09-28 昆明市延安医院 Screening and constructing method of primary hepatocyte klotho gene transduction stem cells
AU2022270075A1 (en) 2021-05-04 2023-11-09 Regeneron Pharmaceuticals, Inc. Multispecific fgf21 receptor agonists and their uses
CA3224026A1 (en) * 2021-06-30 2023-01-05 Board Of Regents, The University Of Texas System Polypeptides targeting cd70-positive cancers
CA3232472A1 (en) 2021-09-23 2023-03-30 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-klb antibodies and uses
TW202334205A (en) * 2021-12-30 2023-09-01 大陸商上海津曼特生物科技有限公司 Anti-[beta]Klotho antibody and use thereof
CN115197300B (en) * 2022-05-17 2023-05-05 四川大学华西第二医院 Protein with non-sequence specificity and high affinity for RNA and application thereof

Family Cites Families (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (en) 1979-07-11 1985-06-05 味の素株式会社 blood substitute
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
ATE37983T1 (en) 1982-04-22 1988-11-15 Ici Plc DELAYED RELEASE AGENT.
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
DE3853515T3 (en) 1987-05-21 2005-08-25 Micromet Ag MULTIFUNCTIONAL PROTEINS WITH SPECIFIC OBJECTIVES.
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
KR900005995A (en) 1988-10-31 1990-05-07 우메모또 요시마사 Modified Interleukin-2 and Method of Making the Same
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
WO1991006287A1 (en) 1989-11-06 1991-05-16 Enzytech, Inc. Protein microspheres and methods of using them
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
ATE164395T1 (en) 1990-12-03 1998-04-15 Genentech Inc METHOD FOR ENRICHMENT OF PROTEIN VARIANTS WITH MODIFIED BINDING PROPERTIES
EP0517895B1 (en) 1990-12-14 1996-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
DE69229477T2 (en) 1991-09-23 1999-12-09 Cambridge Antibody Tech Methods for the production of humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
NL9101953A (en) 1991-11-21 1993-06-16 Seed Capital Investments TESTING DEVICE CONTAINING A PLATE WITH A MULTIPLE OF WELLS WITH AN ASSOCIATED DOSING DEVICE, AND A KIT INCLUDING THESE DEVICES AND USE OF THE DEVICES.
ES2241710T3 (en) 1991-11-25 2005-11-01 Enzon, Inc. PROCEDURE TO PRODUCE MULTIVALENT PROTEINS FROM UNION TO ANTIGEN.
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
ES2202310T3 (en) 1991-12-13 2004-04-01 Xoma Corporation METHODS AND MATERIALS FOR THE PREPARATION OF VARIABLE DOMAINS OF MODIFIED ANTIBODIES AND THEIR THERAPEUTIC USES.
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
DE69333807T2 (en) 1992-02-06 2006-02-02 Chiron Corp., Emeryville MARKERS FOR CANCER AND BIOSYNTHETIC BINDEPROTEIN THEREFOR
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
AU690528B2 (en) 1992-12-04 1998-04-30 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
GB9225453D0 (en) 1992-12-04 1993-01-27 Medical Res Council Binding proteins
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
CZ25697A3 (en) 1994-07-29 1997-09-17 Smithkline Beecham Plc Novel compounds
EP0805678B1 (en) 1995-01-05 2003-10-29 THE BOARD OF REGENTS acting for and on behalf of THE UNIVERSITY OF MICHIGAN Surface-modified nanoparticles and method of making and using same
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
ATE238668T1 (en) 1995-01-17 2003-05-15 Brigham & Womens Hospital RECEPTOR-SPECIFIC TRANSEPITHELIAL TRANSPORT OF IMMUNOGENS
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
AU710347B2 (en) 1995-08-31 1999-09-16 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
JP4046354B2 (en) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Immunoglobulin-like domain with increased half-life
CA2248868A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
ATE355371T1 (en) 1996-12-26 2006-03-15 Kyowa Hakko Kogyo Kk PROTEIN HAVING AN ACTIVITY OF SUPPRESSING AGING
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US20020042367A1 (en) 1997-11-25 2002-04-11 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20020012961A1 (en) 1999-04-15 2002-01-31 Genentech, Inc. Fibroblast growth factor- 19
US20060246540A1 (en) 1997-08-26 2006-11-02 Ashkenazi Avi J Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6806352B2 (en) 1997-09-17 2004-10-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
NZ503343A (en) 1997-09-17 2002-09-27 Genentech Inc Secreted and transmembrane polypeptides and use to induce apoptosis of tumour cells
US20030113718A1 (en) 1997-09-17 2003-06-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US20030108983A1 (en) 1997-09-17 2003-06-12 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (en) 1997-10-23 2000-04-17 Biogram Ab Active substance encapsulation process in a biodegradable polymer
MXPA00004256A (en) 1997-11-03 2005-07-01 Human Genome Sciences Inc Vegi, an inhibitor of angiogenesis and tumor growth.
US20040126852A1 (en) 1997-11-25 2004-07-01 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity
US20050026832A1 (en) 1997-11-25 2005-02-03 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US20020155543A1 (en) 1997-11-25 2002-10-24 Genentech, Inc. Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity and related disorders
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
WO2000042072A2 (en) 1999-01-15 2000-07-20 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000060085A1 (en) 1999-04-02 2000-10-12 Millennium Pharmaceuticals, Inc. Fibroblast growth factor-20
US7390879B2 (en) 1999-06-15 2008-06-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7129072B1 (en) 1999-08-30 2006-10-31 New York University Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factor
JP2001072607A (en) 1999-09-03 2001-03-21 Kyowa Hakko Kogyo Co Ltd New capillary endothelial function improvement
US7459540B1 (en) 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
AU7368100A (en) 1999-09-10 2001-04-10 Curagen Corporation Fibroblast growth factor polypeptide and nucleic acids encoding same
US6797695B1 (en) 1999-10-22 2004-09-28 Kyoto University Human FGF-20 gene and gene expression products
US6716626B1 (en) 1999-11-18 2004-04-06 Chiron Corporation Human FGF-21 nucleic acids
ATE446365T1 (en) 1999-11-18 2009-11-15 Novartis Vaccines & Diagnostic HUMAN FGF-21 GENE AND GENE EXPRESSION PRODUCTS
AU1415501A (en) 1999-11-19 2001-06-04 Kyowa Hakko Kogyo Co. Ltd. Novel polypeptide, novel dna, novel anitbody and novel transgenic animal
DE10160151A1 (en) 2001-01-09 2003-06-26 Ribopharma Ag Inhibiting expression of target gene, useful e.g. for inhibiting oncogenes, by administering double-stranded RNA complementary to the target and having an overhang
US20010044525A1 (en) 2000-01-05 2001-11-22 Conklin Darrell C. Novel FGF Homolog zFGF12
EP1246843A1 (en) 2000-01-05 2002-10-09 ZymoGenetics, Inc. Novel fgf homolog zfgf12
US20020081663A1 (en) 2000-01-05 2002-06-27 Conklin Darrell C. Novel FGF homolog ZFGF11
AU2631001A (en) 2000-01-05 2001-07-16 Zymogenetics Inc. Novel fgf homolog zfgf11
JP2005508131A (en) 2000-02-15 2005-03-31 アムジェン インコーポレイテッド Fibroblast growth factor-23 molecule and uses thereof
US20060160181A1 (en) 2000-02-15 2006-07-20 Amgen Inc. Fibroblast Growth Factor-23 molecules and uses thereof
US20030180312A1 (en) 2000-02-22 2003-09-25 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2001249125A1 (en) 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
WO2001066596A2 (en) 2000-03-08 2001-09-13 Chiron Corporation Human fgf-23 gene and gene expression products
AU5056501A (en) 2000-03-31 2001-10-08 Nobuyuki Itoh Fibroblast growth factor-like molecules and uses thereof
US20030065140A1 (en) 2000-04-03 2003-04-03 Vernet Corine A.M. Novel proteins and nucleic acids encoding same
JP2002112772A (en) 2000-07-10 2002-04-16 Takeda Chem Ind Ltd New polypeptide and its dna
KR20090036151A (en) 2000-07-19 2009-04-13 인디애나 유니버시티 리서치 앤드 테크놀로지 코포레이션 Novel fibroblast growth factor (fgf23) and methods for use
CA2416538A1 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20070037165A1 (en) 2000-09-08 2007-02-15 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US7265210B2 (en) 2000-09-15 2007-09-04 Genentech, Inc. Anti-PRO9821 antibodies
EP1197755A1 (en) 2000-10-11 2002-04-17 Pepscan Systems B.V. Identification of protein binding sites
US7537902B2 (en) 2000-10-24 2009-05-26 Emory University Methods and kits using a molecular interaction between a Smurf-1 WW domain and LIM mineralization protein isoforms
IL139380A0 (en) 2000-10-31 2001-11-25 Prochon Biotech Ltd Active variants of fibroblast growth factor
AU2002230531A1 (en) 2000-11-22 2002-06-03 Bayer Corporation Use of fgf-19 for inhibiting angiogenesis
US20020151496A1 (en) 2000-12-08 2002-10-17 Bringmann Peter W. Novel fibroblast growth factors
DE10100588A1 (en) 2001-01-09 2002-07-18 Ribopharma Ag Inhibiting expression of target genes, useful e.g. for treating tumors, by introducing into cells two double-stranded RNAs that are complementary to the target
DE10100587C1 (en) 2001-01-09 2002-11-21 Ribopharma Ag Inhibiting expression of target genes, e.g. oncogenes, in cells, by introduction of complementary double-stranded oligoribonucleotide, after treating the cell with interferon
US7164007B2 (en) 2001-06-20 2007-01-16 Genentech, Inc. Anti-PR020044 antibodies
ES2405551T3 (en) 2001-10-01 2013-05-31 Dyax Corporation Multicatenary eukaryotic presentation vectors and uses thereof
WO2003035842A2 (en) 2001-10-24 2003-05-01 Dyax Corporation Hybridization control of sequence variation
AU2003225903A1 (en) 2002-03-21 2003-10-08 Curagen Corporation Methods of using farnesoid x receptor (fxr) agonists
US6987121B2 (en) 2002-04-25 2006-01-17 Smithkline Beecham Corporation Compositions and methods for hepatoprotection and treatment of cholestasis
JP2003334088A (en) 2002-05-22 2003-11-25 Pharma Design Inc HUMAN-DERIVED NEW Klotho-LIKE PROTEIN AND ITS GENE
AU2003239966B9 (en) 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
EP1553912A4 (en) 2002-06-07 2007-08-08 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2004026228A2 (en) 2002-09-18 2004-04-01 Eli Lilly And Company Method for reducing morbidity and mortality in critically ill patients
US20050181375A1 (en) 2003-01-10 2005-08-18 Natasha Aziz Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
JP2006240990A (en) * 2003-05-15 2006-09-14 Kirin Brewery Co Ltd Klotho protein and anti-klotho protein antibody and use of them
DK1641483T3 (en) 2003-06-12 2008-06-02 Lilly Co Eli Fusion Proteins
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
KR20060135648A (en) 2003-12-10 2006-12-29 일라이 릴리 앤드 캄파니 Muteins of fibroblast growth factor 21
EP2194064A1 (en) 2004-05-13 2010-06-09 Eli Lilly & Company FGF-21 fusion proteins
JP2006016323A (en) 2004-06-30 2006-01-19 Hiroshima Industrial Promotion Organization Physiologically active biomaterial
EP1789443A1 (en) 2004-09-02 2007-05-30 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1789442B1 (en) 2004-09-02 2009-09-30 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1817335A2 (en) 2004-10-29 2007-08-15 Genentech, Inc. Disruptions of genes encoding secreted proteins, compositions and methods relating thereto
CA2586201A1 (en) 2004-11-03 2006-05-11 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
JP2006158339A (en) 2004-12-09 2006-06-22 Kyoto Univ betaKlotho GENE, Cyp7al GENE, AND THEIR USE
US7655627B2 (en) 2004-12-14 2010-02-02 Eli Lilly And Company Muteins of fibroblast growth factor 21
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
CA2614039C (en) 2005-07-22 2015-10-13 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20090081658A1 (en) 2005-08-24 2009-03-26 Abdelmajid Belouchi Genemap of the human genes associated with crohn's disease
US20090312265A1 (en) 2006-02-10 2009-12-17 Dermagen Ab Novel antimicrobial peptides and use thereof
WO2008021196A2 (en) 2006-08-09 2008-02-21 The Mclean Hospital Corporation Methods and compositions for the treatment of medical disorders
AU2007293465A1 (en) 2006-09-01 2008-03-13 American Type Culture Collection Compositions and methods for diagnosis and treatment of Type 2 Diabetes
WO2008052796A1 (en) 2006-11-03 2008-05-08 U3 Pharma Gmbh Fgfr4 antibodies
CA2711267C (en) 2007-01-03 2018-07-10 California Stem Cell, Inc. Stem cell growth media and methods of making and using same
US8012931B2 (en) 2007-03-30 2011-09-06 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
ES2665996T3 (en) 2007-04-02 2018-04-30 Genentech, Inc. Klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance
WO2008123625A1 (en) 2007-04-06 2008-10-16 National Institute Of Advanced Industrial Science And Technology Method for activating receptor by cofactor and method for utilizing ligand activity
US7537903B2 (en) * 2007-04-23 2009-05-26 Board Of Regents, The University Of Texas System FGF21 upregulates expression of GLUT-1 in a βklotho-dependent manner
US10555963B2 (en) 2007-05-08 2020-02-11 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho protein and related compounds for the treatment and diagnosis of cancer
WO2008135993A1 (en) 2007-05-08 2008-11-13 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho protein and related compounds for the treatment and diagnosis of cancer
EP2036539A1 (en) 2007-09-11 2009-03-18 Novo Nordisk A/S Stable formulations of amylin and its analogues
US20120142546A1 (en) 2007-12-10 2012-06-07 The Johns Hopkins University Hypomethylated genes in cancer
EP2080812A1 (en) 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
US8420088B2 (en) 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
US20090226459A1 (en) 2008-01-29 2009-09-10 Cold Spring Harbor Laboratory Role of fgf-19 in cancer diagnosis and treatment
WO2009117622A2 (en) 2008-03-19 2009-09-24 Ambrx, Inc. Modified fgf-23 polypeptides and their uses
NZ579566A (en) 2008-03-19 2013-01-25 Ambrx Inc Modified fgf-21 polypeptides and their uses
WO2009116861A2 (en) 2008-03-21 2009-09-24 Podiceps B.V. Diagnostic of pre-symptomatic metabolic syndrome
JOP20190083A1 (en) 2008-06-04 2017-06-16 Amgen Inc Fgf21 mutant fusion polypeptides and uses thereof
FR2933702A1 (en) 2008-07-08 2010-01-15 Sanofi Aventis SPECIFIC ANTAGONISTS OF FGF-R4 RECEPTOR
WO2010006214A1 (en) 2008-07-09 2010-01-14 Ambrx, Inc. Fgf-21 neutralizing antibodies and their uses
US8338569B2 (en) 2008-08-04 2012-12-25 Five Prime Therapeutics, Inc. FGFR extracellular domain acidic region muteins
SG195542A1 (en) 2008-10-10 2013-12-30 Amgen Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
US20120035105A1 (en) 2009-01-09 2012-02-09 Sdg, Inc. Insulin Therapies for the Treatment of Diabetes, Diabetes Related Ailments, and/or Diseases or Conditions Other Than Diabetes or Diabetes Related Ailments
US20100274362A1 (en) 2009-01-15 2010-10-28 Avner Yayon Cartilage particle tissue mixtures optionally combined with a cancellous construct
LT2393828T (en) 2009-02-03 2017-01-25 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
AR076541A1 (en) 2009-05-05 2011-06-22 Amgen Inc MUTANTS OF FGF21 AND USES OF THE SAME
CA2760674A1 (en) 2009-05-05 2010-11-11 Amgen Inc. Fgf21 mutants and uses thereof
US8461111B2 (en) 2009-05-20 2013-06-11 Florida State University Research Foundation Fibroblast growth factor mutants having improved functional half-life and methods of their use
WO2010139741A1 (en) 2009-06-04 2010-12-09 Novartis Ag Fgf-21 for treating cancers
US20120172298A1 (en) 2009-06-11 2012-07-05 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
JP2012530493A (en) 2009-06-17 2012-12-06 アムジエン・インコーポレーテツド Chimeric polypeptides and uses thereof
CN101993485B (en) 2009-08-20 2013-04-17 重庆富进生物医药有限公司 Peptide analog homologous dimer capable of accelerating insulin secretion and application thereof
CN102656266B (en) 2009-10-15 2016-08-03 霍夫曼-拉罗奇有限公司 There is the chimeric fibroblast growth factor of the receptor-specific of change
US8889621B2 (en) 2009-10-30 2014-11-18 New York University Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia
SG177025A1 (en) * 2010-06-21 2012-01-30 Agency Science Tech & Res Hepatitis b virus specific antibody and uses thereof
US8372952B2 (en) 2009-12-02 2013-02-12 Amgen Inc. Binding proteins that bind to human FGFR1C, human β-klotho and both human FGFR1C and human β-klotho
UA109888C2 (en) * 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
WO2011084808A2 (en) 2009-12-21 2011-07-14 Amunix Operating Inc. Bifunctional polypeptide compositions and methods for treatment of metabolic and cardiovascular diseases
EP2460527A1 (en) 2010-01-21 2012-06-06 Sanofi Pharmaceutical composition for treating a metabolic syndrome
US20110195077A1 (en) 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
EP2558497A2 (en) 2010-04-15 2013-02-20 Amgen Inc. Human fgf receptor and beta-klotho binding proteins
EP2558115B1 (en) 2010-04-16 2019-07-31 The Salk Institute for Biological Studies Methods for treating metabolic disorders using fgf
JP2013533227A (en) 2010-06-08 2013-08-22 ノヴォ ノルディスク アー／エス FGF21 analogs and derivatives
CN103415300B (en) 2010-07-20 2018-02-23 诺沃—诺迪斯克有限公司 FGF21 compounds end modified N
CN103221039A (en) 2010-09-09 2013-07-24 三叶草私人有限公司 Airway administration of angiogenesis inhibitors
US8993727B2 (en) 2010-09-22 2015-03-31 Amgen Inc. Carrier immunoglobulins and uses thereof
CN102464712A (en) 2010-11-11 2012-05-23 重庆富进生物医药有限公司 Deletion human fibroblast growth factor 21 variant and conjugate thereof
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
BR112013015861A2 (en) 2010-12-22 2018-06-05 Marcadia Biotech Inc methods for reducing weight gain or inducing weight loss, and for treating hyperglycemia, reducing blood glucose levels, or normalizing blood glucose levels.
WO2012086809A1 (en) 2010-12-24 2012-06-28 独立行政法人産業技術総合研究所 Accurate and highly sensitive method for measuring activity of human fgf19 and agent for regulating activity of human fgf19
JP5977814B2 (en) 2011-04-08 2016-08-24 アムジエン・インコーポレーテツド Method for treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
WO2012140650A2 (en) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
US20140189893A1 (en) 2011-05-10 2014-07-03 Amgen Inc. Method of identifying compounds that specifically modulate the interaction of fgfr1 and beta klotho
PE20140995A1 (en) 2011-05-16 2014-08-23 Genentech Inc FGFR1 AGONISTS AND THEIR METHODS OF USE
US9574002B2 (en) * 2011-06-06 2017-02-21 Amgen Inc. Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
KR20140039278A (en) 2011-06-08 2014-04-01 드노보 바이오파마 (항주) 리미티드 코포레이션 Methods and compositions of predicting activity of retinoid x receptor modulator
US20140294820A1 (en) 2011-06-24 2014-10-02 University Of Miami Fibroblast growth factor receptor inhibition for the treatment of disease
AU2012279237B2 (en) 2011-07-01 2016-09-29 Ngm Biopharmaceuticals, Inc. Compositions, uses and methods for treatment of metabolic disorders and diseases
EP2548570A1 (en) 2011-07-19 2013-01-23 Sanofi Pharmaceutical composition for treating a metabolic syndrome
WO2013027191A1 (en) 2011-08-25 2013-02-28 Novartis Ag Methods and compositions using fgf23 fusion polypeptides
WO2013033452A2 (en) 2011-08-31 2013-03-07 Amgen Inc. Method of treating or ameliorating type 1 diabetes using fgf21
UY34347A (en) 2011-09-26 2013-04-30 Novartis Ag DUAL FUNCTION PROTEINS TO TREAT METABOLIC DISORDERS
TWI593708B (en) 2011-09-26 2017-08-01 諾華公司 Fusion proteins for treating metabolic disorders
AR087973A1 (en) 2011-10-04 2014-04-30 Lilly Co Eli VARIATIONS OF FACTOR 21 GROWTH OF FIBROBLASTS
CA2854720C (en) * 2011-11-11 2018-12-18 Rinat Neuroscience Corp. Antibodies specific for trop-2 and their uses
WO2013109856A2 (en) 2012-01-18 2013-07-25 Genentech, Inc. Methods of using fgf19 modulators
US9475856B2 (en) 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
JP2013194049A (en) 2012-03-23 2013-09-30 Kazuo Todokoro Composition and method for amplifying human hematopoietic stem cell
EP2833892A4 (en) 2012-04-02 2016-07-20 Moderna Therapeutics Inc Modified polynucleotides for the production of oncology-related proteins and peptides
WO2013156920A1 (en) 2012-04-16 2013-10-24 Tel Hashomer Medical Research Infrastructure And Services Ltd. Klotho variant polypeptides and uses thereof in therapy
CA2869320A1 (en) 2012-05-15 2013-11-21 Eli Lilly And Company Therapeutic uses of fibroblast growth factor 21 variant proteins to increase bone formation or depositions
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9422353B2 (en) 2012-06-11 2016-08-23 Eli Lilly And Company Fibroblast growth factor 21 variant, composition , and uses thereof
TWI513705B (en) 2012-06-11 2015-12-21 Lilly Co Eli Fibroblast growth factor 21 proteins
CN109627239B (en) 2012-07-11 2021-10-12 缆图药品公司 Inhibitors of fibroblast growth factor receptors
TW201420606A (en) 2012-08-22 2014-06-01 Lilly Co Eli Homodimeric proteins
MX2015002985A (en) 2012-09-07 2015-06-22 Sanofi Sa Fusion proteins for treating a metabolic syndrome.
ES2828505T3 (en) 2012-11-28 2021-05-26 Ngm Biopharmaceuticals Inc Compositions and methods for the treatment of metabolic disorders and diseases
US9290557B2 (en) 2012-11-28 2016-03-22 Ngm Biopharmaceuticals, Inc. Compositions comprising variants and fusions of FGF19 polypeptides
US9273107B2 (en) 2012-12-27 2016-03-01 Ngm Biopharmaceuticals, Inc. Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
RU2675514C2 (en) 2012-12-27 2018-12-19 ЭнДжиЭм БАЙОФАРМАСЬЮТИКАЛЗ, ИНК. Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
WO2014152090A1 (en) 2013-03-14 2014-09-25 Georgetown University Compositions and treatments of metabolic disorders using fgf binding protein 3 and fgf 19
WO2014149699A1 (en) 2013-03-15 2014-09-25 Eli Lilly And Company Bifunctional protein
CA2928135A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Mutated fibroblast growth factor (fgf) 1 and methods of use
EP3062881B1 (en) 2013-10-28 2019-10-02 NGM Biopharmaceuticals, Inc. Cancer models and associated methods
TWI728373B (en) 2013-12-23 2021-05-21 美商建南德克公司 Antibodies and methods of use
DK3097122T3 (en) 2014-01-24 2020-08-10 Ngm Biopharmaceuticals Inc ANTIBODIES BINDING BETA-KLOTHO DOMAIN 2 AND METHODS OF USING IT
US10398758B2 (en) 2014-05-28 2019-09-03 Ngm Biopharmaceuticals, Inc. Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions
AU2015277438B2 (en) 2014-06-16 2020-02-27 Ngm Biopharmaceuticals, Inc. Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases
CA2964782A1 (en) 2014-10-23 2016-04-28 Ngm Biopharmaceuticals, Inc. Pharmaceutical compositions comprising peptide variants and methods of use thereof
WO2016073855A1 (en) 2014-11-07 2016-05-12 Ngm Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders
WO2017019957A2 (en) 2015-07-29 2017-02-02 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
EP3377090B1 (en) 2015-11-09 2021-04-07 NGM Biopharmaceuticals, Inc. Methods for treatment of bile acid-related disorders
EP3503882A4 (en) 2016-08-26 2020-07-29 NGM Biopharmaceuticals, Inc. Methods of treating fibroblast growth factor 19-mediated cancers and tumors
WO2018044778A1 (en) 2016-08-29 2018-03-08 NGM Biopharmaceuticals, Inc Methods for treatment of bile acid-related disorders

Also Published As

Publication number Publication date
ES2808340T3 (en) 2021-02-26
EP3097122B1 (en) 2020-05-06
KR102489475B1 (en) 2023-01-20
LT3097122T (en) 2020-07-27
JP2022153375A (en) 2022-10-12
US20190106490A1 (en) 2019-04-11
PE20170256A1 (en) 2017-04-22
JP2017507652A (en) 2017-03-23
WO2015112886A2 (en) 2015-07-30
CN106662577B (en) 2020-07-21
PH12016501644B1 (en) 2016-11-07
IL246921B (en) 2019-09-26
ES2808340T9 (en) 2021-03-05
US10093735B2 (en) 2018-10-09
CA2937898A1 (en) 2015-07-30
RU2016130128A (en) 2018-02-27
PL3097122T3 (en) 2020-10-19
US20150210764A1 (en) 2015-07-30
EP3097122B9 (en) 2020-11-11
KR20160125381A (en) 2016-10-31
MX2016009555A (en) 2016-12-08
ZA201605151B (en) 2020-12-23
US10744191B2 (en) 2020-08-18
RU2016130128A3 (en) 2018-09-04
BR112016017248A2 (en) 2017-10-03
HRP20200881T1 (en) 2020-09-04
MY191944A (en) 2022-07-20
US9738716B2 (en) 2017-08-22
UA119863C2 (en) 2019-08-27
DK3097122T3 (en) 2020-08-10
AU2015209131B2 (en) 2020-06-25
US20230256070A1 (en) 2023-08-17
RS60593B1 (en) 2020-08-31
IL246921A0 (en) 2016-09-29
US20210030857A1 (en) 2021-02-04
SG10201806108TA (en) 2018-08-30
US11596676B2 (en) 2023-03-07
EP3097122A2 (en) 2016-11-30
NZ722377A (en) 2022-09-30
CY1123163T1 (en) 2021-10-29
AU2015209131A1 (en) 2016-08-11
CN106662577A (en) 2017-05-10
JP2020169173A (en) 2020-10-15
PH12016501644A1 (en) 2016-11-07
JP7436571B2 (en) 2024-02-21
BR112016017248A8 (en) 2018-04-17
CL2016001868A1 (en) 2017-07-21
EP3738981A1 (en) 2020-11-18
HUE050279T2 (en) 2020-11-30
SI3097122T1 (en) 2020-07-31
PT3097122T (en) 2020-07-21
WO2015112886A3 (en) 2015-10-01
RU2701434C2 (en) 2019-09-26
JP6837840B2 (en) 2021-03-10
US20180100014A1 (en) 2018-04-12
EP3097122A4 (en) 2017-09-20

Similar Documents

Publication Publication Date Title
IL279606A (en) Anti-trem2 antibodies and methods of use thereof
IL246921B (en) Binding proteins and methods of use thereof
HK1251158A1 (en) Pd-1 binding proteins and methods of use thereof
IL261666A (en) Binding proteins and methods of use thereof
HK1249445A1 (en) Anti-sortilin antibodies and methods of use thereof
IL259495A (en) Antibodies and methods of use thereof
HK1252698A1 (en) Anti-siglec-9 antibodies and methods of use thereof
HK1252696A1 (en) Anti-siglec-7 antibodies and methods of use thereof
SG10201912150TA (en) Anti-trem2 antibodies and methods of use thereof
ZA202001985B (en) Anti-htra1 antibodies and methods of use thereof
EP3172224A4 (en) Factor h binding protein variants and methods of use thereof
PL3100050T3 (en) Immobilized proteins and use thereof
IL247448A0 (en) Peptides and methods of use